Valbiotis SA (FR:ALVAL) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Valbiotis SA is set to launch its innovative dietary supplement, Valbiotis®PRO Metabolic Health, in France by early 2025. This plant-based product targets metabolic disorders like dysglycemia and type 2 diabetes, with its effectiveness backed by extensive clinical testing. The company aims to leverage the successful strategy of its previous product, Valbiotis®PRO Cholesterol, for this launch.
For further insights into FR:ALVAL stock, check out TipRanks’ Stock Analysis page.